-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo Nordisk's Frehemgo Wins Approval for Haemophilia A in Europe

MT Newswires·11/15/2026 00:11:52
Listen to the news
12:11 AM EST, 11/15/2026 (MT Newswires) -- Novo Nordisk's (NOVO-B.CO) Frehemgo received marketing authorization from the European Commission for haemophilia A in adults and children, according to a Nov. 13 release. Generically known as denecimig, the drug was approved for once-monthly, once-every-two-weeks, or once-weekly dosing using a single-use pre-filled pen to prevent or lower the frequency of bleeding episodes. The decision was supported by the Frontier clinical trial program, in which denecimig significantly cut annualized bleeding rates compared with prior clotting factor prophylaxis and on-demand treatment in people with haemophilia A, with or without inhibitors. The Danish pharmaceutical company will roll out Frehemgo in the first European countries in the year ahead. The treatment also has clearance in Saudi Arabia and is under review in the US.